TERT and glioblastoma: The detection sensitivity of epidermal growth factor receptor variant III (EGFRvIII) was improved by FUS-BBBO from 7% to 65%, and the telomerase reverse transcriptase (TERT) promotor mutation C228T from 14% to 46% in the mouse glioblastoma model.